// App-Quantinova.ai

TPS4148 : REMINET: A European, multicentre, PHASE II/III randomized double-blind, placebo-controlled study evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.

Researchers

Presenter

  • Come Lepage

Principal Investigators

  • Jean-Louis Legoux

  • Karine Le Malicot

  • Rosine Guimbaud

  • David Tougeron

  • Guillaume Cadiot

  • Frederic Di Fiore

  • Denis Michel Smith

  • Karine Bouhier Leporrier

  • Olivia Hentic

  • Astrid Lievre

  • Roger Faroux

  • Nadia Bouarioua

  • Marianne E. Pavel

  • Ivan Borbath

  • Juan W. Valle

  • A Rinke

  • Michel Ducreux

  • Thomas Walter

Medical Centers

  • CHU Le Bocage HGE, INSERM U866, Dijon, France

  • La Timone University Hospital, Marseille, France

  • Centre Hospitalier Regional, Orleans, France

  • FFCD, Dijon, France

  • University Hospital of Rangueil, Toulouse, France

  • Gastroenterology Department, Poitiers University Hospital, Poitiers, France

  • Robert-Debre Hospital, Reims, France

  • Digestive Oncology Unit, IRON group, Rouen Hospital, University of Normandy, Rouen, France

  • Hopital Saint-Andre, Bordeaux, France

  • Centre Hospitalier Universitaire Cote de Nacre, Caen, France

  • Department of Hepato-Gastroenterology, Beujon Univerisyt Hospital, Clichy, France

  • CHU Pontchaillou, Rennes, France

  • Centre Hospitalier Departemental Vendee, La Roche-Sur-Yon, France

  • CHU Saint-Etienne, Saint Etienne, France

  • Charite-University Medicine Berlin, Berlin, Germany

  • Department of Gastroenterology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium

  • University of Manchester, Manchester, United Kingdom

  • Division of Gastroenterology and Endocrinology, University Hospital Marburg (UKGM), Marburg, Germany

  • Institut Gustave Roussy, Service d'Oncologie Digestive, Villejuif, France

  • Department of Medical Oncology, Hospices Civils de Lyon Edouard Herriot Hospital, University of Lyon, Lyon, France

Locations

  • France

  • Germany

  • United Kingdom

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Lanreotide

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • II/III

Study Id's

  • NCT02288377

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved